Armistice Capital LLC has recently announced that it has increased stake in Zomedica Pharmaceuticals Corp. (AMEX:ZOM) by 126.29%. After grabbing 15.32 million shares, the institutional investor is now in possession of 8.55 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 2.72% having worth around $2.42 million. Moreover, Millennium Management LLC increased its share by 0.98 million to have a control over 0.98 million shares. And BlackRock Fund Advisors raised its holdings to 0.93 million shares by acquiring 0.93 million shares or 0.17% of the stake.
Zomedica Pharmaceuticals Corp. (ZOM) concluded trading on 08/27/20 at a closing price of $0.12, with 40.29 million shares of worth about $4.83 million changed hands on the day. Weekly performance of the stock remained negative as price took a plunge of -8.76% during that period and on Thursday the price saw a gain of about 1.89%. Currently the company’s common shares owned by public are about 564.05M shares, out of which, 510.05M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 1 analyst is covering the ZOM stock and their offered price forecasts bring an average price target of $0.50. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $0.50 and could fall to a lowest price of $0.50. Analysts also issued an outlook of 2.00 for the Zomedica Pharmaceuticals Corp. stock for next 12 months. However, touching the estimated high of $0.50 would mean a gain of 76.0% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Total Stock Market Index, USAA Extended Market Index Fund, and Gabelli Equity Trust are the top 3 mutual funds which are holding stakes in Zomedica Pharmaceuticals Corp. Vanguard Total Stock Market Index is currently holding 7.96 million shares of worth totaling $1.26 million. The company recently came buying 0.0 shares which brought its stake up to 1.41% of the company’s outstanding shares. USAA Extended Market Index Fund bought 19861.0 shares, after which its hold over company’s outstanding shares expand to 0.01%, leaving 31916.0 shares with the mutual fund that have a worth of about $5043.0. Gabelli Equity Trust, after buying 8688.0 shares, have now control over 0.00% of the stake in the company. It holds 0.0 shares of worth $1373.0.
Zomedica Pharmaceuticals Corp. (AMEX: ZOM) started trading at $0.12, below $0.0 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $0.12, or with a gain of 1.89%. Stock saw a price change of -8.76% in past 5 days and over the past one month there was a price change of -24.91%. Year-to-date (YTD), ZOM shares are showing a performance of -62.57% which decreased to -62.45% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.11 but also hit the highest price of $0.50 during that period. While comparing its average daily trading volume of 58.69 million shares, we see that about 40.29 million changed hands on the day. The stock is currently trading -14.35% below its 20-day simple moving average (SMA20), while that difference is down -27.12% for SMA50 and it goes to -44.52% lower than SMA200.
Armistice Capital LLC acquired 15.32 million shares of Zomedica Pharmaceuticals Corp. having value of about $2.42 million. Data submitted at the U.S SEC by Armistice Capital LLC revealed that the firm now holds 8.55 million shares in the company valued at close to $1025706.36, or have control over 126.29% stake in the company. Zomedica Pharmaceuticals Corp. (AMEX: ZOM) currently have 564.05M outstanding shares and institutions hold larger chunk of about 6.40% of that. Holding of mutual funds in the company is about 5.72% while other institutional holders and individual stake holders have control over 9.51% and 1.42% of the stake respectively.
The stock has a current market capitalization of $73.01M and its 3Y-monthly beta is at -0.12. It has posted earnings per share of -$0.10 in the same period. It has Quick Ratio of 15.30 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ZOM, volatility over the week remained 7.45% while standing at 5.58% over the month.
Analysts are in expectations that Zomedica Pharmaceuticals Corp. (ZOM) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter ESPS is $0 and it is -$0.02 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.02 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -4.50% while it is estimated to increase by 33.30% in next year.
Analysts at 1 brokerage firms have issued recommendations for the Zomedica Pharmaceuticals Corp. (ZOM)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.